GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2011

WuXi Takes Over Antibody and Research Reagents Firm Abgent

WuXi Takes Over Antibody and Research Reagents Firm Abgent

Acquisition will bring WuXi new product lines for drug discovery and basic research, together with Abgent’s facilities in China and San Diego.[Scott Maxwell -]

  • Sino-U.S. firm WuXi PharmaTech acquired Abgent, an antibody and peptide reagents firm specialized in the provision of antibody reagents for research use, therapeutic antibody development, and peptides and proteins for research and diagnostics.

    WuXi claims the acquisition will provide it with new product lines for drug discovery and basic research, together with Abgent’s facilities in Suzhou, China and in San Diego. “Abgent has built a successful integrated development and production platform of catalog and customized antibody reagents for the global research reagent market,” comments Ge Li, Ph.D., WuXi chairman and CEO. “WuXi’s broad capabilities and customer relationships can take Abgent to the next level.”

    WuXi is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the U.S., which provides a broad and integrated portfolio of laboratory and manufacturing services from discovery to commercialization. Its operations are divided into two segments.  The laboratory services division offers a full range of discovery and development services for pharmaceuticals and biologics, along with development and testing services for biotherapeutics and medical devices, and comprehensive toxicology services. WuXi’s manufacturing services operation provides intermediates and active pharmaceutical ingredients, cell banking services, and cGMP manufacturing for cellular therapeutics and combination/tissue-based products.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »